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Abstract
Pharmaceutical companies have traditionally placed little emphasis on supply chain efficiencies and
operations costs. With the changing landscape of expiring intellectual property rights and
increased market segmentation, the need for improved supplier relations and inventory
management is becoming paramount.
This thesis presents a study of a procurement system within a biopharmaceutical company. The
many sources of variation in delivery lead times from both suppliers and internal departments
coupled with variation in manufacturing demand, has resulted in excess raw-material inventory at
the company. By using discrete-events-simulation software to model the system and its inputs, we
generate insights that can help the materials management team maximize their efforts to improve
the system performance. In this particular case, it was found that reducing supplier lead time
variability was far more effective in reducing the need for inventory than reducing average lead
times or even internal lead times from the Quality Control department.
The pharmaceutical company involved in this study would be best served by focusing its efforts on
working with suppliers to increase the consistency of delivery for their raw materials. This
increased consistency will allow them to reduce total inventory costs by reducing the variability of
the raw-material supplies.
Thesis Supervisor: Dr. Mahender Singh
Title: Research Director - Supply Chain 2020
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1 Introduction
1.1 Background and Motivation
The pharmaceutical industry is unique from other industries in several aspects. Traditionally,
pharmaceutical companies have focused on patient treatment and drug development and not
operational efficiency or supply chain effectiveness. Because of high gross margins and the purpose
of the drugs, the cost of a lost sale is very high both financially and for the health of individuals.
These companies, therefore, have often pushed for high service levels without great consideration
of inventory management or manufacturing excellence.
Several trends within the pharmaceutical industry are forcing companies to change, however.
Expiring intellectual property rights and increased competition are forcing companies to reexamine
their strategies and operations (Singh, 2005). The influence of contract manufacturers who are
more effective at managing operational costs is also driving the industry to re-examine its options.
Traditionally, the pharmaceutical companies, also known as big pharma, relied heavily on the
discovery of blockbuster drugs - drugs with annual sale of USD 1 Billion or more - for their success.
But of late this model has been challenged due to a poor pipeline of successful drugs to replace the
current blockbuster drugs for which patents will soon expire. However, within the broad industry
of pharmaceuticals is a smaller subset of growing "bio-pharmaceutical" companies that have been
successful in developing unique and innovative drugs. These companies are using biological
advances to change the nature of the pharmaceutical industry.
Furthermore, a unique movement within the bio-pharmaceutical segment of the industry has
emerged in the last decade. Companies have begun to vie for smaller and segmented, yet highly
lucrative, markets. These markets are characterized by patients with rare life-altering and life-
threatening diseases. Because of high development costs and corporate interests in common
conditions for the sake of volume, these patients have, until recently, had little recourse for
treatments and drugs. But with the aid of government and insurance subsidies, it has become
economically feasible for corporations to provide treatments for those with these rare diseases, and
also feasible for people with these rare conditions to purchase the same treatments.
Revolutionary technologies are allowing companies to "grow" enzymes to replace those lacking in
individuals and causing health problems. These enzyme replacement drugs are created with
processes and materials that are closely kept and safeguarded. Unfortunately, however, because of
the unique industry attributes (high cost of a lost sale, small specialty markets etc.) vendors and
internal departments have not been held to normal manufacturing and supply chain standards.
Rapid company growth has also provided an atmosphere where many companies have had to
"scramble" to assemble supply chain capabilities to support the burgeoning demand. This explosive
growth necessitates that materials be in place and drugs delivered to the needing patients before
structure can be injected into procurement systems.
Specifically, in material procurement from the various vendors, significant opportunities exist for
supply chain improvement and collaboration. In general, the importance of the availability of
finished products to serve the final consumers dictates most supply chain decisions, which has
resulted in large amounts of inventory throughout the system. Consequently, there is ample
opportunity to reduce inventories and reduce costs related to holding inventory without sacrificing
drug availability.
The "newness" of the industry and the rapid growth of biopharmaceutical companies have resulted
in a lack of development of proper supply chain and inventory management practices. Fire fighting
is the norm for material management teams as they scramble to keep up with growing demand and
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manufacturing requirements. Regulatory restrictions coupled with high quality standards further
complicate any improvement initiative.
Also, a unique set of business parameters in the industry mean that traditional supply chain metrics
and methods may not be appropriate. Inventory management in the bio-pharmaceutical segment
can be especially difficult: long manufacturing lead times, the "life and death" nature of products
and variable demand dictate a new approach to an old problem.
1.2 ABC Pharmaceuticals as an Inventory Case Study
NOTE: With the purpose of protecting the proprietary information of the pharmaceutical company
studied in this thesis, all company and material titles have been removed and replaced with proxy
values. The company is referred to as ABC Pharmaceuticals or ABC and specific materials are referred
to as Material 1, Material 2, etc. The numbers included have not been modified.
ABC Pharmaceuticals is a bio-pharmaceutical company that manufactures many drugs (biologically
based and otherwise) that are used to treat various diseases. An in-depth analysis of the
procurement and quality control process for ABC Pharmaceuticals is provided as an example for
demonstration of inventory sensitivity to changes in lead time length and variability. An
examination of Quality Control processes is also presented. There are many inputs in ABC's supply
chain that could have been modeled and incorporated into the scope of this thesis, but for the sake
of time and resources, only the first stages from material procurement to manufacturing availability
are included in this study.
This thesis describes ABC Pharmaceutical's management of inventory for the production of a single
drug substance. Within that single drug substance, an in-depth analysis is provided for six distinct
materials or "ingredients". Two methods are used to make recommendations for their inventory
levels and management policies:
1. Other industries with similar problems and constraints will be examined and
appropriate methods will be applied to ABC's policies.
2. A simulation model will be developed to determine appropriate inventory levels under
different scenarios.
The drug addressed in this thesis is controlled by a single purchasing/materials management group
that is accountable to the manufacturing group for material availability and quality. All materials
used in the production of the drug and all decisions concerning quality control (QC) and vendor
selection are dictated by this single group. A very simplified overview of the procurement and
material inspection process is shown in Figure 1-1. This flow includes only a few nodes and arcs to
include: Purchase Order issued, vendor lead time, Quality control, and availability for
manufacturing.
PO Issued Quality Control 7 Available for
"\Manufa cturing
Vendor Lead Time Quality Control Lead Time
Figure 1-1 - Simplified Process Flow Representation of ABC's Material Procurement Process
The central goal of the material management team is to provide materials for the production of
drug-substance without fail to the manufacturing team. This goal requires them to carry enough
inventory to buffer the variation in demand from manufacturing and variation in vendor and QC
lead times. Secondary goals for the department include reducing costs related to carrying
inventory and managing that inventory.
Another area of focus is the QC department of ABC Pharmaceuticals. Because of the nature of
pharmaceuticals, documentation and control of these materials must be of the highest quality.
Many of the materials are shipped from vendors with documentation but may have quality
problems, while other materials are not sent as per the quality specifications or are adversely
affected by the specific QC procedures and how they are treated. Most of the time when a problem
is identified with a "lot" of materials, there is a resultant delay associated with that problem in the
QC process. Granularity of these problems and their associated delays are incorporated into the
study of this system. Because the lead-times within the QC department are so closely tied to the
problems associated with material lots, it is appropriate to detail their effects in the model.
Specific insights gained from this analysis will be limited to application within the company under
investigation, but general recommendations may be appropriately applied and valid in similar
companies under similar assumptions and circumstances.
1.3 Analysis Structure
Because of the complexity of the variations involved with the procurement of the pharmaceutical
materials, a mathematical model is not appropriate for estimating inventory impacts and changes in
policy based on vendor lead time and QC improvements. After a basic understanding of the
problem and situation was conveyed, it was decided that a computer simulation would be the most
appropriate tool to assist in the process of understanding and analyzing the dynamics of ABC's
procurement flow. Simulation software has assisted in estimating a model that accurately reflects
the system and its reaction to certain changes.
By simulating the variations associated with vendor lead times, QC process times and the demand
from manufacturing, the system response to buffer inventory was observed. Changes in these
inputs as a basis for hypothetical scenarios resulted in changes in inventory levels and holding
costs. A more detailed account of the methods and results associated with this model and its
estimations are included in Chapters 3 and 4 respectively.
This thesis presents the data from various scenarios that give ABC pharmaceuticals motivation and
direction to concentrate their ongoing improvement efforts in recommended areas. Several
recommendations are proposed based on the results of the simulation and the detailed study of the
business and procurement process.
To properly convey the subject matter in this thesis, it is organized in the following manner.
Chapter 2 presents a thorough examination of the extant literature pertaining to the problem.
Chapter 3 outlines, in detail, the methods used to dissect and analyze the data and inputs. Chapter
4 presents the results and data gathered through the simulation and mathematical analysis portion.
Chapter 5 offers specific recommendations and possibilities for academic and industry application
and Chapter 6 presents conclusions. Appendix and Reference sections are also included to present
cited material and additional information not included in the main text.
2 Literature Review
Several factors influence the reliability and availability of materials to manufacturing in the bio-
pharmaceutical segment. Because of the complexity of the system and multiple factors that
contribute to inventory levels, a comprehensive study of an entire comparable system poses a
formidable challenge. In the system that is addressed in this paper, raw materials are bought from
vendors and must be available for production on certain dates (Singh, 2005). Long and variable lead
times are coupled with internal service variation and frequent changes in manufacturing schedule
to meet similarly variable demand patterns. Most of the research in this field leans on
mathematical models to deal with distinct aspects of this problem.
There has been limited research on the pharmaceutical industry supply chain as a whole. Many of
the unique issues, disadvantages and advantages as they relate to supply-chain functions were
compiled and demonstrated by Singh (2005). His research addresses the differences between
pharmaceutical companies and typical industries. These differences include the emphasis on
development and new drug introduction. These factors and the historically high margins and
profitability have fostered an environment in which supply-chain functions have not received the
attention or emphasis that they deserve.
Singh touches upon the problem of raw material difficulties, but does not go into depth on the
subject. Whereas, Goren and Clapp describe how FDA regulations require large capital investments
by suppliers to comply with the law (Goren & Clapp, 2005). Because of this barrier to entry, it is
often difficult to dual-source materials or for buyers to have leverage with suppliers based on
threat of alternatives in the market.
Beyond the relevant literature related to the biopharmaceutical industry, we will review sources
and practices outside of the pharmaceutical industry that can be applied to this specific situation.
15
There is extensive literature that relates directly to specific attributes of the system under
investigation. These areas of research can be categorized as dealing with either the supply side or
the demand side influences. The applicable research can be divided into the following areas on the
supply side:
1. Varying and long supplier lead times in procurement (2.1.1)
2. Long and varying internal lead times (2.1.2)
And on the demand side:
1. Highly variable short term demand coupled with predictable long term demand (2.2.1)
2. High service levels for material availability to manufacturing (2.2.2)
2.1 Supply
2.1.1 Varying Supplier Lead Times
The problem of varying lead time in procurement can be perplexing and several methods for
managing this variation have been proposed in the literature. Louly and Dolgui (2009) propose a
method in which several components, all with varying lead times and lead time factors, are brought
in for assembly of a single product. Their method for planning the orders of the products involves a
simple process of determining individual component safety stocks.
Just as safety stocks in finished goods inventory buffer against variation in customer demand,
component safety stocks buffer against changes and uncertainty in supplier performance and lead
time. This method, of using time as a buffer, applies to bio-pharmaceutical manufacturing as
multiple chemicals and ingredients are brought in to contribute to a single final batch of products.
It is important to recognize that coordinating the availability of all components is key since a batch
of final product cannot be made unless all components are available. This method, however,
applies only when orders from suppliers will be used for multiple production runs. If orders are
made on a single-production-run basis, keeping a safety stock of a component may not make sense.
In the case of the bio-pharmaceutical industry, orders from suppliers are often completely used up
by a single production run. That makes the use of a "safety stock" system for components
applicable only for materials that can be used in multiple batches or for multiple products. In the
case where an entire order is consumed in a single production run and, since production batches
cannot be initiated until all components or ingredients are available, another method must be used.
Kumar (1989) describes a simple method, similar to the "safety stock" method, where lead times
are variable and the production batch has a defined start time but can be delayed by the late
delivery of any single component. Determining when to order components so that costs (holding
costs and production delay costs) are minimized and service levels to the customer are still met is
of utmost importance. Instead of using safety stock to buffer uncertainty, Kumar describes a
method that uses time to buffer uncertainty. Essentially, materials are ordered well in advance
based on historical information so that lead time uncertainty is accounted for in planning.
Bollapragada, Rao and Zhang (2004) talk about combining random supply and random demand in
an inventory system. They use mathematical methods to estimate appropriate buffer inventory
levels. Much of their research centers on a multi-echelon inventory environment, but many of the
insight gained from combining supply and demand uncertainty mathematically are still applicable.
As discussed in section 2.2.1 in this chapter, the aj term in equation 2.1 is generally used to
calculate safety stock needs per the demand variability. However, Silver, Pike and Peterson (1998)
also demonstrate the same variability term can be converted to determine lead time variability in
supply for a specific material inventory.
2.1.2 Internal Lead Time Variability
Wilson (2010) describes that anytime there is variation in a system, there must be something to
buffer that variation. Buffers can come in any of three forms: inventory, time, or capacity. In the
case of the internal system investigated in this thesis, all three of these buffers could apply. Raw
material inventory currently buffers the lead times associated with QC processing the lots. Extra
time built into the ordering of materials could also buffer the lead time variation. Capacity is also a
concern that could alleviate the variation in the Quality Control department.
2.2 Demand
2.2.1 Highly Variable short term demand
Variability in demand and the effects on required inventory levels can be characterized for the most
part with mathematical models. Silver Pike and Peterson demonstrate that under the assumption
that demand variation can be aggregated and under the assumption of normally distributed
demand equation 2.1 can be used (Silver et al., 1998).
SS = kOL 2.1
where:
SS = Safety Stock
k = is a safety factor related to a desired service level
u = the standard deviation of forecast errors over the period of duration L
This model is useful under any demand regime where inventory can be monitored on a continuous
or near-continuous basis. The model is also applicable under circumstances of low demand
variability.
2.2.2 High service Levels to an Internal Customer
High service levels to internal customer can be related to high service levels respective to any
customer or demand. Service level targets can be used to determine inventory levels
mathematically as shown in Equation 2.1. The "k" parameter can be inflated to mathematically
represent better service level to a final customer (Silver et al., 1998).
Beyond mathematical models and equations lies an application aspect of inventory control. Articles
by Ouellet, et al. (1982) and separately Gross, Harris and Robers (1972) demonstrate how to
properly implement mathematically derived service levels into real-world inventory situations.
These applications are important for validation of the mathematical models. Mathematical models
are not useful unless they have been implemented and validated in real world settings. For this
reason, the two case studies cited here are important.
2.2.3 Unpredictable events/market uncertainty
To a certain extent, statistical models can account for uncertainty and wild fluctuations in demand
or supply. However, most of the time, large events that may affect inventory levels can't be planned
or not factored into inventory levels. Wild fluctuations that cannot be predicted by demand
forecasts are hard to plan, especially when methods used to analyze costs and profits only are used.
Lau (1980) addresses this unpredictability by using the newsboy model to optimize parameter
other than profit. His notion of utility may be adapted to integrate a notion of risk aversion in
inventory planning.
2.3 Summary
There are many sources in literature that describe mathematically how systems can properly buffer
against uncertainty using inventory, time or capacity. There are also pieces of important literature
that demonstrate the application of mathematical models in real-world applications. The
combination of these sources provides an important backdrop for the work presented here. In this
thesis, application of inventory policies is modeled using simulation tools. Also, the mathematical
models that underlie inventory policies are used to calculate many of the results from the
simulation model.
3 Methods
We have chosen discrete-event simulation technique to map and analyze the procurement process
at ABC Pharmaceuticals. The simulation model helps to track the impact of lead times and their
variations associated with different raw materials and the attributes of the raw materials.
A base simulation model was created and several variations of the model were also tested. These
variations are referred to as scenarios. The methods and assumptions used to create and analyze
the base model along with the scenario changes are described in this section. Those methods and




* Best practices outside the bio-pharmaceutical industry
Basic Assumptions
* Variations in the system are represented as statistical distributions.
* Structural simplicity is implemented in certain areas of the model to allow easier
understanding and quicker modeling of the system.
" Base-model data is assumed to represent the current state and near-future state of the
procurement system.
Also, just like any model, there are limitations, and some of those limitations are described in
section 3.4 of this chapter.
3.1 Arena Model
The model for this thesis was developed in Arena. Arena is a discrete-event-simulation software
product licensed by Rockwell Automation Technologies Inc. The software is used to create
interactions between processes and entities. Entities are the objects that move through the flow
path of the simulation. Processes and decision points determine the attributes and the delays
associated with moving through the system. The entities can be programmed to possess certain
attributes which affect how they are treated by different steps and processes.
Each input to the model (arrivals, delays, attributes, etc.) can be set to statistically resemble real-
world conditions. Probabilistic and stochastic variables can be simulated through computer
generated random variables. The type of probability distribution can range anywhere from
something simple like a discrete uniform distribution to a much more complex user-defined
schedules and sub-models. We are using a combination of mostly uniform, discrete and normal
distributions to characterize the data and input it into the model. A list of model input and the
associated distributions are included in Table A-1 of the Appendix.
3.1.1 Modeling Approach
The model used for this thesis treats individual raw material lots as entities. A single lot in the
model is defined as the quantity that would be ordered for a minimum production run. The reason
lies in the way that the QC data was presented. The Quality Control department measures its own
performance and deals with materials in the form of lots instead of individual units of measure.
The processes used in the model relate to various lead times associated with vendor delivery and
QC inspection. Each lot that enters the system has probability of possessing certain attributes.
These attributes signify errors and problems with the raw materials. QC lead times are directly
linked to the types of problems incoming raw materials possess. A list of the QC problem codes and
the associated delays is included in Table A-4 in the Appendix.
The model was created using historical data from ABC Pharmaceuticals. After the model was run
using historical data and validated (see Section 3.1.2), inputs were changed through a source
spreadsheet file that feeds back into the model. This allows the user to easily "test" scenarios that
may occur in the future, or scenarios that may improve the performance of the model. For example,
the user can reduce vendor lead time on a single material by changing the value in the spreadsheet
and by doing so can quickly see how raw-material inventory levels are affected. These scenarios
are detailed in section 3.2.
A snapshot of the model is shown in Figure 3-1 and Figure 3-2. The model has six main modules
and the sub-models dictate the behavior at the "vendor lead time" module and the "QC" module.
Demand for raw material inventory by manufacturing is also modeled as a random process.
Manufacturing demand is modeled as an independent process in the model. The two processes
work hand-in-hand to represent the real world processes. The models simulate the process in
which manufacturing signals the beginning of a production campaign in a specified amount of time.
This specified time is equal to the combined stated lead times for the material from the Vendor and
through QC (Table A-2 Appendix). When the procurement process receives the signal from
manufacturing, it "orders the materials". When the combined lead time has elapsed, manufacturing
sends a signal to the raw material inventory to release the prescribed number of material lots. The
manufacturing process is diagramed in Figure 3-2.
Figure 3-1 - Procurement process as modeled in Arena for Material 1
Manufacturing Demand
H Combined
MFG Order Signal Stated Lead Demand Signal Dispose 2
Figure 3-2 - Manufacturing demand process as modeled in Arena
Figure 3-3 - Snapshot of the entire model, including the procurement processes for all six
materials on the left and the associated manufacturing demand processes on the right.
3.1.2 Verification and Validation
Any model must be verified and debugged to ensure that any unexpected results are due to
probability and stochasticity and not model or human error. This step can be performed by
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removing all initial probability and variation built into the model and running the model. The
model should perform predictably under the set of ideal circumstances. Adding probabilities and
variation factors individually and independently in the model should also produce a predictable set
of results. The model was verified following this method. All outputs performed predictably with
variation removed.
After the initial model was built, validation step was performed. Since the model is meant to mimic
reality in its current state, it must demonstrate behavior similar to what has been observed by the
bio-pharmaceutical team. To properly validate the base model, output data was shared with the
materials management team at ABC Pharmaceuticals to ensure that it reflected reality.
In this validation phase, the model was run and the output (overall lead times and raw material
inventory requirements) was compared with the data that is being collected empirically. Although
the model will not exactly mirror reality, it should give a reasonable representation of what is being
observed, in other words, the output ranges and averages should be comparable. Without the
validation that the model represents current state system behavior, it is useless to model scenarios
or to even infer possible strategies from the model. The management team at ABC Pharmaceuticals
reviewed early model outputs and determined that they correlated with their knowledge of the
system and the data with which they were familiar.
3.2 Scenario Modeling
Most of the scenarios have been developed in conjunction with the team from ABC Pharmaceuticals.
These scenarios are suggested based on what is thought to be ideal realities and possible
improvements to the current system. Other scenarios are based on "best practices" from outside of
the bio-pharmaceutical industry, or insights gained from testing the model. As mentioned before,
the scenarios are tested by changing model input on the source spreadsheet and running additional
replications of the model. Structural scenarios have not been modeled, although some suggestions
for structural changes are made in the findings of this thesis (Chapter 5).
3.2.1 Vendor Lead Time Scenarios
Vendor lead times comprise two parts: the average lead time and the variation around that average.
Both of these inputs can be important relative to the required inventory levels. That said, all
vendor lead time scenarios were either based on reducing the lead time for a material (by working
with a vendor or changing vendors) or reducing the variability of the lead time. In general, vendors
quote maximum lead times and often deliver early or later than the quoted lead times. The
assumption is that by reducing this uncertainty, inventory levels can be reduced. The model helps
us to predict how the levels could change based on the different lead time parameters.
3.2.2 QC Improvement Strategies
It is much more difficult to predict how certain changes will affect QC lead times. The QC
department at ABC Pharmaceuticals is fairly complex and a simple change to error rates or error
types may not have a linear effect on lead times. Similar to section 3.2.1, lead times can be altered
by changing the average or the variation. Additionally, within the QC portion of the model, certain
material attributes that cause added delays within the QC department can be eliminated or
minimized to view the affect on required inventory levels.
3.3 Sensitivity Analysis
To understand the significance of the model, it is important to test its responsiveness to input
changes and to understand the limitations of the model. The sensitivity analysis performed for this
model was important as it increased understanding pertaining to significant and non-significant
results and shed light on which inputs influenced the dependant variables to the greatest extent.
Basic input manipulation very similar to the design of the various scenarios was performed as well
as analysis related to margins of error and confidence intervals.
Because the simulation model is an exercise in statistical manipulation and combination, there is an
inherent margin of error associate with all outputs. To this end, along with normal outputs, the
software has the ability to generate statistically derived margins of error associated with certain
confidence levels. The base model and all the scenarios were developed and simulated with a 95%
confidence interval. The margin for error is especially relevant as cost savings are reported in
Chapter 4.
3.4 Limitations
Simulation models have their own analytical limits. The model is meant to represent reality and to
predict what could happen in the future based on a set of defined circumstances. Unfortunately,
because the model represents a random system and does not encapsulate the infinite detail of the
real-world, the model and its outputs will not and cannot be completely accurate. We can, however,
gain a better knowledge of how a system works by building a representation and testing the
representation to gain important insights.
Another limitation pertains to the inputs to the model. Some assumptions were made that may not
be valid with further collection of data. For example, some inputs were modeled with normal
distributions, but more data may show that they should characterized by alternate distributions.
Also, in the case of the demand from manufacturing, it was difficult to collect accurate data during
the study period. In the instances where data was not readily available, proxy representations were
used in the model based on interviews or empirical estimates given by the ABC Pharmaceuticals
team. Referencing Table A-1 in the Appendix can give a sense of statistical and data limitations
presented here.
4 Results
This chapter summarizes the results from running several versions of the base simulation model. It
highlights important findings that will be discussed further in the conclusions section of this thesis.
After building the model, a sensitivity analysis was performed to better understand the results and
the key drivers to the dependant variable in the model (raw material inventory levels). Some of the
results from the sensitivity analysis are incorporated into the scenario results.
The results from the base model will first be described followed by the several scenarios that were
also developed. For each case (base and scenarios), several variables will be reported. These
include, but are not limited to: appropriate safety stock levels, annual holding costs, vendor lead
times and QC lead times. The variation associated with each of these outputs will also be reported.
In this way each scenario can be compared with the base case and other scenarios with consistent
criteria. The numbers are reported for each of the six included materials.
Additionally, with the exception of the combination scenarios described in Section 4.2.6 of this
chapter, all scenarios were developed to isolate a specific input change so that the change was not
confounded with the presence of other variable changes. For example, in Scenario 1, the vendor
lead time is reduced by 20%. This reduction is made with lead time variation and all QC lead times
remaining consistent. In this way, the policy of reducing vendor lead time can be examined
independent of any other process changes.
NOTE: All simulation results, holding cost and safety stock calculations were made with the
assumptions of a 12% holding cost rate and a z = 3.02 (99.9% Fill Rate).
4.1 Baseline Model Data
The baseline model in this thesis simulated the current materials management process at ABC
Pharmaceuticals. The resultant metric measurements are approximations of real world metrics.
This being said, the insights gained from the data can be used in a relative sense to predict what
could happen at a high level if certain improvements or changes are made to the system.
The base model was developed to represent as closely as possible in the available time, the system
that currently exists at ABC Pharmaceuticals. Running the base case resulted in the model outputs
summarized in Table 4-1.










Total Inventory Value $44,520,980
Safety Stock (Lots)
Holding Cost/year $464
QC WIP (Lots) 55
Safety Stock (Lots) 31
Holding Cost/year $3,079,512
QC WIP (Lots) 11
Safety Stock (Lots) 18
Holding Cost/year $224,198
QC WIP (Lots) 29
Safety Stock (Lots) 20
Holding Cost/year $285,694
QC WIP (Lots) 27
Safety Stock (Lots) 22
Holding Cost/year $16,094
QC WIP (Lots) 24
Safety Stock (Lots) 17
Holding Cost/year $11,219
QC WIP (Lots) 27
As Table 4-1 shows, safety stock quantities vary from 17 to 31 lots and annual holding costs total
more than $5.3 million. Also, the table demonstrates that a large portion of the costs are being
accumulated for a single material, Material 2.
4.2 Scenario Data
Several scenarios were developed and run for comparison against the baseline model. Raw-
materials inventory was the main dependent variable that was measured. Closely related to
inventory levels are the calculated holding costs. Most of the scenarios are presented in the form of
the following question: How is inventory affected and how much money is saved in holding costs if
a certain improvement or change can be made to the system? Improvements in lead times and
reduction in variability were also analyzed for each scenario.
Further scenarios detail situations in which certain Problem Codes can be eliminated within the QC
process. The final two scenarios describe combinations of the other basic scenarios. One of these
combines the three error-elimination scenarios into one and the final scenario combines an
increase in vendor lead time coupled with decreased lead time variability for a single material. The
scenarios and the resultant data associated with those scenarios are presented in Sections 4.2.1
through 4.2.7.
4.2.1 Scenario 1 - Decreased Vendor Lead Times
In this scenario, and its sub-scenarios, lead times were decreased proportionally across the board
for all suppliers. For example, if a supplier has an average delivery lead time of 50 days and the
scenario calls for a 20% improvement, this simulation was run with an average lead time of 40
days. In this scenario, the variability in lead times for each supplier remained constant. The
inventory improvements and holding cost savings are shown below in Table 4-2.







Table 4-2 and Figure 4-1 show that as vendor lead times are decreased, cost savings increase. A
lead time reduction of 10% results in a $246,000 savings while decreasing lead times by 50%
results in a much more significant savings of $3,286,000. Larger decreases in vendor lead times
result in greater cost savings.
Safety stock values are also lower as the lead times are shortened. As an example, at a 10%
reduction in lead time the safety stock for Material 2 is 31 lots. When the lead times are decreased








Holding Cost Savings over base $25,352 $143,231 $352,047
Available Inventory Reduction $132,970 $1,136,674 $2,952,571
Total Inventory Savings (Year 1) $245,955 $1,336,826 $3,285,775
Safety Stock (lots) 25 25 24
Holding Cost/year $470 $464 $456
Safety Stock (lots) 31 29 27
Holding Cost/year $3,071,297 $2,964,473 $2,767,362
Safety Stock (lots) 18 17 16
Holding Cost/year $221,798 $215,952 $207,321
Safety Stock (lots) 20 19 18
Holding Cost/year $280,483 $273,659 $262,480
Safety Stock (lots) 22 21 20
Holding Cost/year $16,140 $15,411 $14,888
Safety Stock (lots) 17 17 16
Holding Cost/year $11,038 $10,822 $10,367
Vendor Lead Time Cost Savings
$3,500,000 -- - - -- --
$000,000 - ---- - - --
$2,500,000 - - --- .- - - --..-
$2,000,000 - - - - -
$1,500,000 -- -- - ..
$-- - -- ------
10% Vendor Lead 25%Vendor Lead 50%Vendor Lead
Time Reduction Time Reduction Time Reduction
Figure 4-1 - Vendor Lead Time Reduction Cost Savings
4.2.2 Scenario 2 - Decrease Vendor Lead Time Variability
This scenario models the case where vendor-lead-time variability is decreased by proportional
amounts. An example of a scenario detailing a 20% improvement in lead-time-variability across all
vendors would be the following: Currently, a vendor has an average lead time of 50 days with a
standard deviation of 20 days. The scenario would model that same vendor having a lead time of
50 days (same) with a standard deviation of 16 days. The proportional improvement is applied to
all vendors for this scenario.
The changes to raw-material inventory and subsequent holding cost are displayed in the Table 4-3.











Figure 4-2 and Table 4-3 demonstrate the significant savings that can be realized by reducing the
variability of vendor lead times. When vendor lead time variation is reduced by 25%, holding costs
are reduced by over $400,000. When that same lead time variability is reduced by 75%, the holding
cost savings increase to over $1.1 million. Total inventory savings are much higher, but increase
comparable with the changes in variability.
Safety stocks are decreased significantly as well. Twenty-four lots are needed for the safety stock of
Material 1 when the vendor lead time variability is reduced by 10%. Only 21 lots are needed when








Savings over base $415,934 $852,406 $1,141,465
Available inventory Reduction $3,431,712 $7,089,284 $9,558,539
Total Inventory Savings (Year 1) $3,882,049 $7,955,788 $10,653,673
Safety Stock 24 22 21
Holding Cost/year $448 $421 $412
Safety Stock 27 23 20
Holding Cost/year $2,719,962 $2,323,216 $2,056,002
Safety Stock 16 15 14
Holding Cost/year $207,559 $192,645 $183,682
Safety Stock 17 15 14
Holding Cost/year $252,982 $227,769 $209,115
Safety Stock 19 17 16
Holding Cost/year $14,341 $13,193 $12,337
Safety Stock 15 14 13
Holding Cost/year $10,085 $9,224 $8,609
Vendor Lead Time Variation Cost
Savings
$12,O00O - -- - - - --O
S $1050,O 0 -O--- ----
S$4,000,000 - -.--- -- - -~
$4,000,000 -------
25%Vendor Lead 50%Vendor Lead 75%Vendor Lead
Time Variability Time Variability Time variability
Reduction Reduction Reduction
Figure 4-2 -Vendor Lead Time Variation Reduction Cost Savings
4.2.3 Scenario 3 - Decreased Quality Control Lead Times
Similar to Scenario 1, Quality Control lead times can be decreased proportionally to gain
improvements in inventory and holding costs. Those associated improvements are shown in Table
4-4.
-Summary of QC Lead Time Reduction Simulation Results
10% QC Lead 25% QC Lead
Time Reduction Time Reduction
50% QC Lead
Time Reduction
As can be seen in Table 4-4 and Figure 4-3, the savings resulting from decreases in QC lead times
are not as clear as they are for vendor lead times. In fact, only the savings related to a 50%
reduction in QC lead times is significantly lower than for the same decrease in vendor lead time.
The QC savings at that level are over $4.3 million. This result is evident in the lot quantities
required for the safety stocks. The lots composing the safety stocks are only reduced by one lot
overall for all the materials. Material 3 is the only material for which less safety stock is needed at
the 50% reduction level. These savings therefore, can be attributed to the reduction in QC WIP









Holding Costs $5,232,467 $5,206,901 $4,883,246
Savings over base $110,051 $135,616 $459,272
Available Inventory Reduction $227,264 -$427,439 $843,358
QC Inventory Reduction $689,828 $1,557,573 $2,983,906
Total Inventory Savings (Year 1) $1,027,143 $1,265,750 $4,286,536
Safety Stock (lots) 24 24 24
Holding Cost/year $463 $461 $452
QC WIP 53 50 45
Safety Stock (lots) 30 31 30
Holding Cost/year $3,056,842 $3,130,305 $2,987,051
QC WIP 10 10 9
Safety Stock (lots) 18 18 17
Holding Cost/year $222,210 $224,482 $221,352
QC WIP 28 26 24
Safety Stock (lots) 20 20 20
Holding Cost/year $283,045 $286,124 $280,063
QC WIP 26 24 21
Safety Stock (lots) 22 21 22
Holding Cost/year $16,260 $16,002 $16,049
QC WIP 23 21 19
Safety Stock (lots) 17 17 17
Holding Cost/year $11,090 $11,101 $11,012
QC WIP 26 24 21
QC Lead Time Cost Savings
$5,000,000 -r--- ---- -- --.- , -.-.-
$3,500,000
8 $3,00 ,00 --- - --o - - - - -
$2,000,000
$1,500,000 -- --------
$1,000,000- - - --
02 $500,000- - -
10%QC Lead Time 25%QC Lead Time 50% QC Lead Time
Reduction Reduction Reduction
Figure 4-3 - QC Lead Time Reduction Cost Savings
4.2.4 Scenario 4 - Decreased Quality Control Lead Time Variability
Following the pattern that Scenario 2 laid out, QC lead time variability can be decreased
proportionally and modeled to simulated projected changed in inventory and holding cost levels.
Table 4-5 shows those changes.









Figure 4-4 and Table 4-5 demonstrate a lack of clear evidence to show that reducing QC lead time
variability leads to holding cost savings. All cost savings values are not very significant and
therefore not considered relevant.
The same trend is manifest in the safety stocks. Safety stocks are only reduced by one lot overall for
the 75% lead time variability reduction. The other two levels of variability reduction result in









Holding Costs $5,362,170 $5,347,658 $5,290,900
Savings over base -$19,652 -$5,140 $51,618
Available Inventory Reduction ($) -$288,067 -$93,766 $357,696
QC Inventory Reduction $124,298 $50,933 $72,453
Total Inventory Savings (Year 1) -$183,422 -$47,973 $481,766
Safety Stock 24 23 22
Holding Cost/year $446 $434 $424
QC WIP 55 55 56
Safety Stock 20 20 20
Holding Cost/year $283,336 $284,174 $287, 290
QC WIP 27 27 27
Safety Stock 18 18 18
Holding Cost/year $222,523 $222,645 $224,055
QC WIP 28 29 29
Safety Stock 21 21 21
Holding Cost/year $15,850 $15,937 $15,858
QC WIP 23 23 23
Safety Stock 31 31 30
Holding Cost/year $3,118,489 $3,094,381 $3,035,858
QC WIP 11 11 11
Safety Stock 17 17 17
Holding Cost/year $11,106 $10,862 $10,772
QC WIP 27 27 27
QC Lead Time Variation Reduction
Cost Savings







Variab uction REDUX REDUX
-$200,000 I- - -- - - ~ ~~~
-$300,000
Figure 4-4 - QC Lead Time Variation Reduction Cost Savings
4.2.5 Scenario 5 - QC Problem Code Elimination
The QC process in the model includes 23 error codes where each error code is associated with a
delay for each material in the QC process. By eliminating certain QC errors, QC lead times may
decrease and result in inventory savings. This is done in the model by allowing material entities to
still gain the error code attribute, but setting the delay associated with that attribute to zero.
Essentially, the error code has no resultant delay and the entity is treated as though it went through
QC "right first time".
Not all codes were modeled individually for this model, but the few that were are detailed in Table
4-6. All error code eliminations were modeled individually and independently to gain the most
insight on which error codes are causing the greatest delays and costing the most per the system.
40
In this way, error code elimination can be associated with inventory improvements and QC lead
time improvements.







Only the elimination of Problem Code 12 proved to be significant in the simulation. Regardless of
the negative or positive results associated with the removal of the other two problem codes, the
monetary results are small enough and not considered statistically valid.
One reason for the insignificant results can be derived from Figures Figure 4-5 and Figure 4-6. It is
easy to see that "on time" lots and lots associated with Problem Code 14 compose the largest








Holding Cost Savings over base $117,889.21 -$1,048.13 $4,328.79
Available Inventory Reduction $397,697.08 -$102,685.71 -$286,207.42
QC Inventory Reduction $584,713.01 $93,951.32 $322,280.71
Total Inventory Savings (Year 1) $1,100,299.30 -$9,782.52 $40,402.08
Safety Stock 25 25 25
Holding Cost/year $468.02 $463.88 $467.93
QC WIP 55 52 56
Safety Stock 30 31 31
Holding Cost/year $3,032,163.80 $3,088,873.03 $3,109,703.62
QC WIP 11 11 11
Safety Stock 18 18 18
Holding Cost/year $223,252.26 $227,322.80 $225,744.91
QC WIP 23 29 25
Safety Stock 20 20 20
Holding Cost/year $286,260.04 $286,536.99 $28,8,531.63
QC WIP 27 27 27
Safety Stock 22 21 21
Holding Cost/year $16,108.37 $15,784.92 $15,965.57
QC WIP 19 19 21
Safety Stock 17 16 17
Holding Cost/year $11,205.69 $10,522.49 $11,113.06
QC WIP 27 18 27
Code 14 because of its general nature - essentially represents a general "late" comment coming
from QC and is most likely comprises multiple smaller problems.
Problem Code Prevalance
ProblemCode 2, Problem




Figure 4-5 - Breakdown of problem codes by percentage of total lots
Problem Code Only Breakdown
Problem Code 2,
6%
Figure 4-6 - Breakdown of problem codes without the "on-time" category
4.2.6 Combination Scenarios
Two combination scenarios were tested. Each one of the combined sets of changes to input was
previously incorporated individually in other scenarios. Both scenarios also attempt to simulate
real world situations. The first scenario presents a situation in which all three problem codes listed
in Section 4.2.5 are "eliminated". Theoretically, the elimination of all three problem codes should
result in an aggregate savings equal to the sum of all the savings from Section 4.2.5.
The other scenario attempts to model a scenario in which the management team is able to negotiate
reduced vendor lead time variability, but only at the cost of an extended lead time. Essentially the
scenario models a vendor who has increased their lead time (by 25%), but is now delivering much
more consistently (75% reduction in variability). Another important note about this scenario is
that the changes are implemented with the supplier that supplies Material 2. Material 2 being the
most costly material in the simulation and its holding costs are generally the largest contributors to
total holding costs.
The summary for the two scenarios is included in Table 4-7.
Table 4-7- Summary of Cost and Safety Stock Reductions for two combined
scenarios
Problem Code
Elimination - All 3 codes
combined
Material 2 Vendor Lead
Time 25% Increase
Lead Time variability 75%
Reduction
Even by eliminating three of the most prominent errors that QC encounters, Table 4-7 shows that
the result is on the same level of significance as the elimination of Problem Code 12 only, as shown
in Table 4-6. In comparison to the base scenario, minimal cost savings are realized with this
combination scenario.
The second combination scenario, however, is extremely revealing. For Materials 2, the vendor








Holding Costs $5,224,628 $4,490,461
Savings over base $117,889 $852,056
Available Inventory Reduction $397,697 $7,154,813
QC Inventory Reduction $584,713 -$54,345
Total Inventory Savings (Year 1) $1,100,299 $7,952,524
Safety Stock 25 25
Holding Cost/year $468 $468
QC WIP 55 55
Safety Stock 30 21
Holding Cost/year $3,032,164 $2,220,616
QC WIP 11 11
Safety Stock 18 18
Holding Cost/year $223,252 $225,926
QC WIP 23 29
Safety Stock 20 20
Holding Cost/year $286,260 $284,391
QC WIP 27 27
Safety Stock 22 21
Holding Cost/year $16,108 $15,987
QC WIP 19 23
Safety Stock 17 17
Holding Cost/year $11,206 $11,215
QC WIP 27 27
savings for this scenario nearly reached the cost savings for the 75% variability reduction scenario
in Section 4.2.2. Even increasing the lead time could not largely offset the savings from decreasing
the variability for this high-cost material. Nearly $8 million in cost savings were predicted by this
scenario.
4.2.7 Scenario Comparison
Vendor Lead Time vs. Lead Time
Variability Reduction
$12,000,000 ---- ------- - -
$5,000,000 --------- -LeadTime Reduction
2 Lead Time Variability
$2,000,000 Reduction
10% 25% 50% 75%
Percentage Reduction
Figure 4-7 - Comparison for vendor lead time reduction and lead time variability reduction
Figure 4-7 shows the comparative savings for decreasing vendor lead time for all Materials (Section
4.2.1) and decreasing the variability while maintaining the same original lead times (Section 4.2.2).
While the reductions are made on slightly different scales (Lead time reduction ranges from 10%-
50% and variability reduction ranges from 25%-75%), it is still easy to see the comparative
disparity between lead time reduction and variability reduction.
While the difference is quite obvious for vendor lead times, the trends are not so discernible for QC
lead time changes. Figure 4-8 attempts to demonstrate the differences.
QC Lead Time Reduction vs. Lead Time
Variability Reduction
$5,0000.0 - - - .-.- --.-
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Figure 4-8 - Comparison for QC lead time reduction and lead time variability reduction
According to the simulated scenarios, the only significant reduction came from a 50% reduction in
QC lead times. This finding seems somewhat counterintuitive, especially when compared to the
similar scenarios for vendor lead times. The odd data point cannot be automatically dismissed, but
is most likely an outlier that can be considered insignificant. Overall, the QC lead times are
significantly shorter with less variability than the vendor lead times. For this reason, they have
much less marginal influence on the response variables in the model.
Greater insight can be gained as all the scenarios are compared in Figure 4-8. In this table, it is easy
to see and compare all of the scenarios. Also, percentage savings not given in the other tables in
this chapter are given here.
Table 4-8 - Scenario comparison for all scenarios including cost savings and percentage






Bose Scenario $5,342,517.60 $30,143,181.87 $14,377,798.15 $49,863,497.62
Available
Holding Cost Inventory QC Inventory Total Inventory
Savings over base Reduction Reduction Savings (Year 1) over base
10% Vendor Lead Time Reduction $26,352.27 $132,969.92 $86,632.32 $245,954.51 not significant*
25% Vendor Lead Time Reduction $143,231.33 $1,136,674.08 $56,920.34 $1,336,825.74 2.7%
50% Vendor Lead Time Reduction $352,047.34 $2,952,570.61 -$18,842.76 $3,285,775.20 6.6%
25% Vendor Lead Time Variation Reduction $415,933.84 $3,431,711.55 $34,403.80 $3,882,049.19 7.8%
50% Vendor Lead Time Variation Reduction $852,405.86 $7,089,284.09 $14,098.05 $7,955,788.00 16.0%
75% Vendor Lead Time Variation Reduction $1,141,464.99 $9,558,539.46 -$46,331.20 $10,653,673.24 21.4%
10% QC Lead Time Reduction $110,051.02 $227,264.27 $689,827.57 $1,027,142.87 2.1%
25% QC Lead Time Reduction $135,616.11 -$427,439.16 $1,557,573.40 $1,265,750.35 2.5%
50% QC Lead Time Reduction $459,271.67 $843,357.58 $2,983,906.32 $4,286,535.57 8.6%
25% QC Lead Time Variation Reduction -$19,652.39 -$288,067.48 $124,297.54 -$183,422.33 not significant*
50% QC Lead Time Variation Reduction -$5,140.01 -$93,766.40 $50,932.98 -$47,973.43 not significant*
75% QC Lead Time Variation Reduction $51,617.81 $357,695.65 $72,452.74 $481,766.19 not significant*
Elimination of Problem Code 22 $117,889.21 $397,697.08 $584,713.01 $1,100,299.30 2.2%
Elimination of Problem Code 13 -$1,048.13 -$102,685.71 $93,951.32 -$9,782.52 not significant*
Elimination of Problem Code 16 $4,328.79 -$286,207.42 $322,280.71 $40,402.08 not significant*
Error Eim 4 - All3 combo $117,889.21 $397,697.08 $584,713.01 $1,100,299.30 2.2%
Single VendorLT.25% up VAR 75% down $852,056.12 $7,154,813.10 -$54,345.47 $7,952,523.74 15.9%
*lf the difference was less than 1.2% or $600,000 it is not statistically significant
As Table 4-8 demonstrates, many of the scenarios modeling QC lead time changes and QC problem
code elimination yield insignificant cost savings. The most significant cost savings are realized as
the parameters representing vendor performance are altered. Reductions in vendor lead times
yield up to 6.6% savings in total inventory costs. These savings come only with great change,
however, as lead times must be reduced by 50% to obtain those results.
The most significant cost savings are predicted with the model by reducing vendor lead time
variability. Reducing vendor lead time variability by only 25% results in 7.8% cost savings. When
variability is reduced by 75%, the savings are significantly more at 21.4%.
The last part to note in this comparison summary is the 16% savings that are predicted by focusing
on a single material and trading variability reduction for increased lead times. The savings
predicted for this situation can be seen in the last row of Table 4-8.
% Total Savings
5 Synthesis and Insights
Based on the results obtained and described in the previous section of this thesis, we synthesize the
findings in this chapter and share some of the key insights gained from the research. The
immediate application of this synthesis is specifically relevant to ABC Pharmaceuticals. However,
the insights shared here can have extended application throughout the pharmaceutical industry as
well as throughout academia and industry.
5.1 Insights
Insights come from more than just the results. As the model was in development, there was a need
to gather data and to better understand ABC's business. This exploration and data mining exercise
was invaluable both for the research team including ABC's management team. Data that they had
not collected previously and data that were not initially considered valuable ended up being critical
in generating insights and understanding. Learning more about ABC's business from the materials
management department as well as from ABC planners and buyers also provided valuable
information that helped explore the problem in a more holistic manner.
5.1.1 Model Development
Any exercise in which a manager attempts to analyze a business case or situation in depth requires
use of data and deep knowledge of the process. Building and using the model that was developed
for this case provided opportunities for the research team to mine and test their data against the
tacit knowledge of the business and the results of the simulations. The ability to control inventory
in this case is based on how well lead time and demand from downstream manufacturing are
controlled and understood. It is also vital to know where to look for data and what to do in
response to certain occurrences.
The simulation exercise also provided insight into the limitations of the methodology. More
qualitative metrics, such as responsiveness and flexibility, were difficult to model. For example, the
model showed that reducing vendor lead times did not have as large an impact as reducing the
variability of those lead times. However, reducing lead times would allow ABC to become much
more responsive to possible product and demand changes. Unfortunately, the simulation model is
not all-inclusive or encompassing.
5.1.2 System Knowledge and Inventory Management
Proper collection and mining of data can yield tremendous benefits. In order to effectively manage
inventory, first and foremost, we need good information. At ABC Pharmaceuticals, the data exists in
many forms and in many places. The difficulty in analysis also arises because we often don't know
what to look for and where to look for it. Several inputs should be well understood to properly
manage raw-material inventory. These inputs may seem obvious but worth reiterating for clarity.
The first important data input is demand from manufacturing. It is not only vital to know the
manufacturing plan, but it is also necessary to know how much the actual manufacturing quantities
may vary from that plan. For example, a campaign may be scheduled for a date several months in
advance. What are the chances that that campaign is pushed back, or moved up? Also, when that
campaign is executed, how closely are the original planned quantities followed? Manufacturing can
change dates of production and production quantities. What is the variability associated with these
changes?
The second input that should be well understood is the lead times from vendors. This data is
readily available at ABC Pharmaceuticals. The data, however, needs to be reviewed often. One way
to monitor vendor performance is with a vendor scorecard. Currently, ABC Pharmaceuticals orders
materials in advance based on stated vendor lead times. A more effective approach could be to
order based on actual lead times, or based on an average lead time with maximum variability
factored in.
The third process/input that is critical to provide raw materials to manufacturing is Quality
Control. This process can be viewed in several ways. From a purely lead-time perspective, QC is
very similar to the vendors. Average lead times can be tracked and materials can be ordered
according to actual lead times. The entire procurement process could also be treated as a separate
business unit and positioning QC an independent corporate service to the business. With this
viewpoint, QC would be more actively managed and viewed as the critical point in the flow of
materials. Either way, a better understanding of what is happening within the department and how
disturbances to the process affect inventory levels is crucial to the continual improvement of the
system performance.
Once a firm knowledge of these inputs is obtained, effective inventory policies can be implemented
confidently. Because of the intricacies of the pharmaceutical industry, recommended inventory
policies may or may not follow traditional methods and mathematical models. But without
sufficient knowledge of the key parameters, an inventory policy is either going to result in too much
inventory (and unnecessary holding costs) or a lack of service to the customer (manufacturing).
Lastly, ABC Pharmaceuticals currently orders materials only when they receive a campaign plan
from manufacturing, and the order is placed for the quantities needed for the specific campaign.
This method, while very transparent, should be further investigated. It is not to assert that the
existing method for obtaining materials is the wrong method; however, with good information
about demand and supply variation, it may be possible and more effective to order materials to
maintain inventory levels instead of ordering per campaign. This is something that can be
investigated further by ABC Pharmaceuticals.
5.1.3 Vendor Management
The data presented in Chapter 4 made two things very clear. First, that it is much more important
to address the variability coming from vendor lead times than it is to reduce those lead times. It is
also clear that one or two of the materials provide the greatest opportunity for cost savings. Also,
as the final scenario results indicate, savings can be achieved even if lead times are increased, as
long as those increases are coupled with a reduction in lead time variability. This conclusion
excludes the consideration of the flexibility and responsiveness that may be sacrificed if lead times
are increased. If only inventory costs are a consideration then reducing variability is much more
important.
Materials arriving late are clearly more harmful, especially in the current system of ordering
materials based on stated lead times. When a material lot arrives late, the lot must either be
expedited through the QC department, or manufacturing must dip into buffer stock to satisfy
demand requirements. Materials arriving early are also detrimental. Assuming that transfer of
ownership occurs when the materials are received by ABC Pharmaceuticals, any material that
arrives early will sit in inventory accruing unnecessary holding costs.
With the understanding that both early and late lots cost money, specific delivery windows should
be set for vendors. These windows should set an expectation for a delivery date as well as giving
the vendors some slack on delivering a little early or late. Material 2 has a stated lead time from the
vendor of 70 days. Data from ABC Pharmaceuticals shows that on average, Material 2 is delivered
13 days early (See Table A-3 in the Appendix) but as a range, it can be delivered anywhere from
160 days early to over 300 days late. The variability associated with these delivery inconsistencies
requires large amounts of inventory to ensure that manufacturing demand is satisfied.
Because the cost of holding inventory is most often associated with the value of the inventory, it is
easy to know which materials are contributing the largest amounts to holding costs. Variability
must be combined with material cost to determine holding cost contribution. If a material is
purchased for $1 million for a specific campaign, but there is no variability in the vendor lead time,
no inventory needs to be held for that material (assuming no demand variability). Inversely, a
material can have low value, with high variability and inventory costs can be significant.
The scenarios included in Chapter 4 repeatedly showed that Material 2 was the largest contributor
to inventory holding costs. Not only does Material 2 have the highest per-lot value, but vendor lead
times and lead time variability are both high for the material as well. If the materials were to be
ranked by impact on holding costs, Material 2 would be a strong number one, with Material 3 being
placed in distant second.
5.1.4 Vendor Negotiation
Proper negotiation of delivery terms will not be effective unless the impact of all factors is well
understood. We recommend that lead time variability reduction is much more effective than actual
lead time reduction. However, reducing variability from vendors is the most powerful lever only up
to a certain point after which shorter lead times become more important. Additionally, supply
chain responsiveness should also be considered when negotiating delivery terms.
Figure 5-1 shows the interplay between vendor lead time and vendor lead time variability and the
effects on inventory reduction.
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Figure 5-1 - Interpolated curves showing inventory savings for lead time improvements
As can be seen in Figure 5-1, for the parameters explored in this study, vendor lead time variability
is a much more impactful lever. However, once variability is improved to a certain level, overall
lead time becomes the more important factor.
This interplay is highly reliant on the variation in demand from manufacturing. When the variation
in demand is doubled (original standard deviation of 2 lots), lead time become a more significant
influence on inventory reduction. This change can be seen in Figure 5-2.
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Figure 5-2- Interpolated curves showing inventory savings for lead time improvements with
demand variability doubled
With demand variation doubled, lead time reduction is more important for every percentage
reduction scenario.
This interplay is derived from mathematical models. Using Equation 2.1 from Chapter 2, we can
determine how demand variability affects inventory levels. To incorporate lead time variability
into the model we can use the Equation 5.1 to determine a new sigma term to substitute the
original at term in Equation 2.1 (Silver et al., 1998).
D = 2 E[L] + y ,'Vcr[L] 5.1
where:
U(DLT) is the Demand Variation over the lead time
U is the standard deviation of the demand for the lead time, squared
E[L] is the expected lead time (lead time average)
p2 is the average demand over the lead time, squared
Var[L] is the variation (standard deviation) of the lead time
General assumptions govern this mathematical model, however. Demand and lead time must be
normally distributed. Also, the assumption of continuous inventory monitoring is used for this
model.
Knowing which factors contribute most to the need to hold inventory is essential in negotiating
delivery terms as effectively as possible with vendors.
5.1.5 Quality Control Management
While many of the scenarios dealing with changes in the Quality Control department did not predict
overly significant savings, it should not be assumed that real-world changes would not yield
positive results. Most of the savings coming from QC change scenarios resulted from the decreased
inventory held up in the QC department. QC changes did not have much effect on buffer
inventories.
Echoing the comments set forth in Section 5.1.3, efforts should be made to improve QC performance
for specific materials to start and eventually focus on overall performance. It costs the most to hold
inventory for Material 2, whether that inventory in available for manufacturing or being process by
QC. Material 2 should be a high priority for the QC department.
Anecdotal accounts of QC identified possible causes for the department's inconsistent performance.
These include problems with incoming materials, lack of staffing and disruptive expedites which
caused late delivery of lots. The legitimacy of each of these complaints needs to be explored.
The problems associated with incoming materials can be separated into two categories: problems
internal to QC, and problems originating with the vendors. When materials come from vendors
with a lack of documentation or even a lack of quality, QC has trouble making the lots available for
manufacturing. The number of these problems could most likely be reduced by working with
individual vendors. The internal QC problems are probably related to the second complaint that QC
is understaffed.
An understaffed QC department will perform similar to a manufacturing process that does not have
sufficient capacity. Many materials will be released to manufacturing on time, while others will be
forgotten or mishandled and QC lead times will become erratic. It can be argued that in a
constrained environment, quality will become a concern and the throughput of the system will also
suffer. Re-work and more quality testing will in turn cause a constant need to resort to fire fighting.
As demand outpaces capacity, expedited orders will cause even more of a disruption in the QC
system. The expedited orders should not be a large problem for QC unless they are understaffed. A
QC department with excess capacity would be able to handle the low number of expedited lots.
5.1.6 Demand Management
Demand variation contributes largely to the need for excessive inventories especially under a high
product availability regime. This thesis did not deal with the management of demand variation.
However, reducing this variation can yield similar benefits as a reduction in the variation in lead
times from vendors and QC.
The underlying demand for many of ABC's finished drugs is fairly predictable and stable. The small
number of consumers makes it easy to predict future demand for a drug. Further investigation may
show that variations in demand are only due to a lack of communication or a misalignment of
supply-chain metrics. Indeed, erratic ordering or scheduling patterns, regardless of the underlying
reason, can reverberate upstream through the supply chain to the point where demand appears to
be extremely variable. This amplification of demand variation can occur even in situations where
the underlying demand is very stable.
5.2 Pharmaceutical Industry Applications
5.2.1 Vendor Power and Regulation Compliance
Many of the suppliers to the pharmaceutical industry are not held to the same lead time standards
as those outside the pharmaceutical industry. This is not to say the suppliers in the industry are
incompetent or do not perform to the standards that are set forth by their customers. Generally,
buyers in the pharmaceutical industry are more concerned with regulation compliance, quality and
availability rather than inventory or raw material delivery performance.
Based on data from ABC Pharmaceuticals, suppliers are generally very good at providing materials
that are of very high quality and arrive with proper documentation. Compared with outside
industries, the quality of the materials they deliver may be much higher but delivery consistency
falls well below other industries standards.
Influencing change in this area may be difficult for ABC Pharmaceuticals, as the company is not a
major player in the broad Pharmaceutical industry. Because of the smaller quantities that ABC
orders for some of its drugs, it may not have the leverage to influence the delivery patterns for
many vendors. However, as described in Chapter 4, ABC Pharmaceuticals may be able to negotiate
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tighter delivery windows by allowing longer lead times. Influencing vendors that provide materials
for the very specific biopharmaceutical segment may be more realistic.
ABC Pharmaceuticals can try to establish standards related to on-time delivery and can attempt to
enforce these standards with all vendors. However, because much of the power may reside with
the suppliers, it may be difficult to ensure compliance to these standards. It may be more effective
to work with suppliers one-on-one to reduce lead time variability and overall performance. Specific
collaboration may be required in the areas of demand planning as well. Or possibly, information
systems may need to be integrated to provide more consistent results
Another difficulty inherent to the biopharmaceutical industry is the issue of dual sourcing raw
materials. Because of the complex nature of the materials and the extra effort surrounding federal
regulations and certification, it is often difficult to find and qualify new vendors. The problem of
proving equivalence when changing a material adds to the challenge.
5.3 Academic Applications and Extensions
5.3.1 Lead Time Reduction vs. Lead Time Variability Reduction
This thesis has shown ample evidence to support the assertion that to reduce inventory it is better
to reduce lead time variability than to reduce the actual lead times for our study. This, however, is
not an assumption that is applicable to any situation. The definition of a couple of key parameters
drove the outcome in the model.
The inventory required to buffer lead time is dependent on the variation triggered by the demand
signal. In the presence of a highly variable demand, the influence of changes in lead times is even
greater in the calculation of safety stock inventory. As demand variation diminishes, lead times
become less impactful. Section 4.2.6 gives a perfect example of this. An already long lead time is
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increased by 25% and the impact fails to offset the savings gained by reducing the variability of the
same lead time.
The demand variation used in the simulation is small compared to the wildly inconsistent delivery
times coming from the suppliers. If these two variation sources were closer in magnitude,
reductions in lead times would have even more influence on the dependent inventory levels.
6 Conclusions
The goal of this thesis was to help ABC Pharmaceuticals better understand the variations that were
driving the decisions in the raw material procurement process. The proposed model is expected to
enhance the operational understanding of the raw material procurement process at ABC
Pharmaceuticals. By modeling and performing sensitivity and scenario analysis using a simulation
model, we were able to predict responses in the system based on several levers or parameters. The
analysis and synthesis yielded insights that were supplemented by information gained by talking
with employees of ABC Pharmaceuticals and applying concepts borrowed from other industries
Analysis made it clear that improving vendor reliability was by far the most important lever for the
modeled system. Vendor lead time reduction is also a tool that can help reduce inventory levels.
Working with vendor to improve both lead times and the consistency of those lead times can result
in a more responsive lead time and more flexibility in ensuring that materials are available for the
manufacturing department.
Another insight gained from the research process, although obvious in hindsight, was that a single
yet very costly material drove most of the cost improvements in the simulations. Not only was the
material very costly, but the variation associated with delivery of the material was high, and the
lead time was long. Focusing efforts on this single product should yield immediate results. This
insight falls in line with the 80/20 rule.
At present the Quality Control department acts as a source of additional variation, albeit to a lesser
degree than the suppliers. This is being caused by a lack of understanding of how the department
can perform more effectively as well as inadequate knowledge of proper staffing requirements. If
the department can be organized and staffed effectively, it can be used as a tool to buffer the
variability originating from vendors instead.
Also related to the QC department, it may not be useful to spend time and energy on eliminating
specific problem codes. As vendor relations improve and more collaboration stems from the
relationships, the problem codes originating from external sources should decrease. Also, as QC
performance improves, the problem codes should also disappear over time. Problem codes are
most likely symptoms of deeper systemic problems. Further improvement opportunities exist if
manufacturing demand can be understood better and collaboration can be extended between the
planning, buying and manufacturing departments. Beyond the specific model, ABC Pharmaceuticals
would benefit by gaining a deeper understanding of various sources of variation in their
environment and learn how these variations affect what they do on a daily basis to order and
manage materials.
6.1.1 Future Research
There are several aspects of ABC's system that lend themselves to a more detailed inspection and
could provide for valuable research. For instance, it would be important to understand why
seemingly predictable demand coming from patients would translate into variable demand
upstream through ABC's supply chain.
The market for the drug being studied has experienced disruptions in the past year. These
disruptions were caused by an inability by a competitor to reliably supply patients with a similar
drug. It would be beneficial for ABC Pharmaceuticals to understand how these disruptions affect
the demand for their products and also how the changes in demand reverberate up the supply
chain. Once the impact of disruptions on the supply chain is understood, ABC Pharmaceuticals can
prepare itself better for similar possibilities in t he future.
A deeper dive into the QC department could merit quite a bit of further research. Process
effectiveness and value stream mapping techniques could be applied in the context to better
understand where the root of the QC problems lay. If the QC department is better understood, ABC
should be able to further reduce variability and subsequently inventory levels.
Appendix A
Table A-1 - Inputs to the procurement model and how they have been represented
statistically
Data Source Distribution Application Level
Stated QC Lead Times ABC Pharmaceutical MRP system Discrete Per Material
Percentage QC delays Data gathered by ABC Pharm. Normal Distribution Per Problem Code
Problem Code Assignment Data gathered by ABC Pharm. Probabilistic Per Entity (single material lot)
Stated Vendor Lead Times ABC Pharmaceutical MRP system Discrete Per Material
Actual Vendor Lead Times Data gathered by ABC Pharm. Normal Distribution Per Material
Time between Manufacturing Campaigns Anecdotal - ABC planner Discrete Campaign
Manufacturing Demand Quantity (Lots) Anecdotal - ABC planner Normal Distribution Campaign
Manufacturing Time Deviation from stated plan Anecdotal - ABC planner Triangular Distribution Campaign
Lot Value ABC Pharmaceutical MRP system Constant Per Entity (single material lot)















Table A-3 - Actual vendor lead times with the variability for each material
Observed Vendor Lead Time















Table A-4 - Percentage Delays associated with the several Problem Codes assigned to
material lots that passed through the QC process. NOTE: 0% in the average delay column
signifies lack of any data points for that problem code.
QC LT % average delay QC LT% delay Std dev
On time -31% 25%
Problem Code 1 52% 30%
Problem Code 2 85% 77%
Problem Code 3 0%* 0%*
Problem Code 4 131% 7%
Problem Code 5 267% 0%
Problem Code 6 117% 93%
Problem Code 7 29% 16%
Problem Code 8 325% 0%
Problem Code 9 164% 56%
Problem Code 10 27% 33%
Problem Code 11 0%* 0%*
Problem Code 12 71% 36%
Problem Code 13 79% 95%
Problem Code 14 28% 15%
Problem Code 15 30% 29%
Problem Code 16 64% 103%
Problem Code 17 9% 10%
Problem Code 18 321% 102%
Problem Code 19 18% 26%
Problem Code 20 75% _%*
Problem Code 21 127% 119%
Problem Code 22 21% 22%
Problem Code 23 164% 135%
Problem Code 24 7% 4%
Problem Code 25 48% 13%
*0% callouts signify a lack of any data points for this problem code, or a single data
point only if the 0% falls in the standard deviation column
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